Neogenomics Stock Investor Sentiment

NEO Stock  USD 17.73  0.17  0.95%   
About 56% of NeoGenomics' investor base is looking to short. The analysis of overall sentiment of trading NeoGenomics stock suggests that many investors are alarmed at this time. NeoGenomics' investing sentiment overview a quick insight into current market opportunities from investing in NeoGenomics. Many technical investors use NeoGenomics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  

NeoGenomics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards NeoGenomics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over six months ago at thelincolnianonline.com         
NeoGenomics, Inc. Expected to Post Q1 2024 Earnings of Per Share
news
over six months ago at businesswire.com         
ROSEN, A LEADING NATIONAL FIRM, Encourages NeoGenomics, Inc. Investors to Inquire About Securities C...
businesswire News
over six months ago at businesswire.com         
ROSEN, A LEADING NATIONAL FIRM, Encourages NeoGenomics, Inc. Investors to Inquire About Securities C...
businesswire News
over six months ago at benzinga.com         
SHAREHOLDER ALERT Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeoGenomics, Inc....
benzinga news
over six months ago at thelincolnianonline.com         
Neo Hits 1-Day Trading Volume of 83.89 Million
news
over six months ago at businesswire.com         
NeoGenomics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
businesswire News
over six months ago at thelincolnianonline.com         
BTIG Research Trims NeoGenomics Target Price to 21.00
news
over six months ago at thelincolnianonline.com         
NeoGenomics Buy Rating Reiterated at Needham Company LLC
news
over six months ago at gurufocus.com         
Unveiling NeoGenomics s Value Is It Really Priced Right A Comprehensive Guide
Gurufocus Stories at Macroaxis
over six months ago at accesswire.com         
Canada Jetlines Announces Closing of Additional Proceeds of 13.5 Million Equity Financing
news
over six months ago at thelincolnianonline.com         
Neo Trading Up 0.2 percent Over Last Week
news
over six months ago at seekingalpha.com         
NeoGenomics ruling seen having limited impact on estimates, Needham says
seekingalpha News
over six months ago at washingtonpost.com         
Altice USA, PENN Entertainment rise Hess, NeoGenomics fall, Thursday, 12282023
Washingtonpost News at Macroaxis
over six months ago at finance.yahoo.com         
NeoGenomics to Appeal Ruling
Yahoo News
over six months ago at thelincolnianonline.com         
Neo Price Hits 13.92
news
Far too much social signal, news, headlines, and media speculation about NeoGenomics that are available to investors today. That information is available publicly through NeoGenomics media outlets and privately through word of mouth or via NeoGenomics internal channels. However, regardless of the origin, that massive amount of NeoGenomics data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of NeoGenomics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of NeoGenomics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to NeoGenomics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive NeoGenomics alpha.

NeoGenomics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Neo Trading Up 1.5 percent Over Last 7 Days
10/17/2024
2
Wall Street Analysts Believe NeoGenomics Could Rally 51.29 percent Heres is How to Trade
11/04/2024
3
Earnings call NeoGenomics sees growth with NGS and new test launches
11/07/2024
4
Disposition of 11336 shares by Hannah Alison L. of NeoGenomics subject to Rule 16b-3
11/15/2024
5
NEO Battery Materials Awarded as Consortium Partner in 20M Recycled Silicon Battery Project by South Korean Government
11/20/2024
6
Acquisition by Sherman Jeffrey Scott of 13005 shares of NeoGenomics subject to Rule 16b-3
11/22/2024
7
Disposition of 6224 shares by Warren Stone of NeoGenomics subject to Rule 16b-3
11/29/2024
8
Neo Medicals Spine Care Platform Fully Approved Under EU Medical Device Regulation Directive
12/02/2024
9
NEO Battery Materials Announces Director Resignation and Updates to Upcoming Corporate Webinar
12/03/2024
10
ConcertAI and NeoGenomics Announce New AI Software-as-a-Service Solution for Hematology Clinical Research
12/05/2024
11
Disposition of 11746 shares by Sherman Jeffrey Scott of NeoGenomics subject to Rule 16b-3
12/06/2024
12
NeoGenomics Inc Unveils Promising Study on ctDNA for Melanoma Recurrence Detection
12/11/2024
When determining whether NeoGenomics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NeoGenomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neogenomics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neogenomics Stock:
Check out NeoGenomics Hype Analysis, NeoGenomics Correlation and NeoGenomics Performance.
To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.
You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeoGenomics. If investors know NeoGenomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeoGenomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
1.306
Earnings Share
(0.61)
Revenue Per Share
5.098
Quarterly Revenue Growth
0.104
Return On Assets
(0.03)
The market value of NeoGenomics is measured differently than its book value, which is the value of NeoGenomics that is recorded on the company's balance sheet. Investors also form their own opinion of NeoGenomics' value that differs from its market value or its book value, called intrinsic value, which is NeoGenomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeoGenomics' market value can be influenced by many factors that don't directly affect NeoGenomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeoGenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeoGenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeoGenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.